Investors: Press Releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven

Regulatory

Allarity Therapeutics Issues Share Units as Payment-In-Kind for Services Rendered During Rights Issue in Q2 2021

Regulatory

Allarity Therapeutics Receives Acceptance & Review Notification from U.S. FDA for Pre-Market Approval Application for Dovitinib-DRP®

Regulatory

Last day of trading with Allarity Therapeutics A/S BTU

Regulatory

Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib

Regulatory

Allarity Therapeutics Completes Oversubscribed Rights Issue

Regulatory

Allarity Therapeutics Publishes E-Poster Detailing the Molecular Pathways Covered by the Dovitinib-DRP® Companion Diagnostic

Regulatory

Allarity Therapeutics Publishes Interim Report for the Period January – March 2021

Regulatory

Allarity Therapeutics Publishes Prospectus Supplement

Non-Regulatory

Allarity Therapeutics Invites Investors for Q1 2021 Report Conference Call

Regulatory

Allarity Therapeutics Secures Investment from 3i Fund for Recapitalization, Transition to Listing on U.S. Nasdaq, and Advancing Pipeline of Priority Oncology Therapeutics

Regulatory

Allarity Therapeutics to Conduct a Rights Issue of New Shares, and Publishes Prospectus regarding the Rights Issue

Regulatory

Allarity Therapeutics Updates Preliminary Timetable for Planned Rights Issue

Regulatory

Allarity Therapeutics To Present a Dovitinib-DRP® e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress

Regulatory

MINUTES OF ANNUAL GENERAL MEETING 2021

Regulatory

Allarity Therapeutics Submits Premarket Approval Application to U.S. FDA for DRP® Companion Diagnostic for Dovitinib

Regulatory

Notice of Annual General Meeting

Regulatory

Allarity Therapeutics Publishes its Annual Report for 2020

Non-Regulatory

Allarity Therapeutics Invites Investors for FY/Q4 2020 Report Conference Call

Regulatory

Allarity Therapeutics plans fully guaranteed rights issue of approximately SEK 100 million

Sign up for press releases

Sign up for press releases and receive relevant information about Allarity Therapeutics A/S.